Click Here

RESPONDENTS REPORTED IMPROVEMENT IN NON-SEIZURE RELATED OUTCOMES:1

87

reported improved alertness, cognition and executive functioning

Group 24536

reported improved emotional and social functioning

85- 81

reported improved language and communication (non-verbal and verbal)

RESPONDENTS REPORTED IMPROVEMENT IN NON-SEIZURE RELATED OUTCOMES:1

81

reported improved alertness, cognition and executive functioning

80

reported improved emotional and social functioning

68- 63

reported improved language and communication (non-verbal and verbal)

BECOME is a global outcomes survey of caregivers of 498 people with LGS or DS that assessed changes in BEhavior, COgnition, and More with EPIDYOLEX® after ≥3 months of treatment, compared to the month prior to initiation1#

FIND OUT MORE

ABOUT EPIDYOLEX® MECHANISM OF ACTION AND PRODUCTION OF EPIDYOLEX®

EPIDYOLEX® provides an alternative mechanism of action for the treatment of LGS, DS and TSC seizures and lacks euphoric effects.

See more

LEARN MORE

ABOUT THE EFFICACY OF EPIDYOLEX®

EPIDYOLEX® has been assessed in 5 Phase III clinical trials within Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS) and Tuberous Sclerosis Complex (TSC) including 938 patients and 3 open-label extension studies.

Discover the results

HOW TO START

TREATMENT WITH EPIDYOLEX®

EPIDYOLEX® is a valuable option for your treatment strategy that can help you address the complexity of LGS, DS and TSC management. Long-term tolerability has been demonstrated as consistent in LGS, DS and TSC.

See details

ABBREVIATIONS

CLB: Clobazam; DS: Dravet syndrome; LGS: Lennox-Gastaut syndrome.

* Clobazam currently does not have marketing authorisation in Norway.

# Survey contained only LGS and DS patients with 55% of paediatric patients and 40% of adult patients also taking CLB.*1 Results were similar across paediatric and adult patients.1

  1. Berg A, et al. Epilepsy Research. 2023;107280:0920-1211.

REFERENCE

  1. Berg A, et al. Epilepsy Research. 2023;107280:0920-1211.

ABBREVIATIONS

CLB: Clobazam; DS: Dravet syndrome; LGS: Lennox-Gastaut syndrome.

FOOTNOTES

* Clobazam currently does not have marketing authorisation in Norway.

# Survey contained only LGS and DS patients with 55% of paediatric patients and 40% of adult patients also taking CLB.*1 Results were similar across paediatric and adult patients.1